Barrett oesophagus

Yonne Peters, Ali Al-Kaabi, Nicholas J. Shaheen, Amitabh Chak, Andrew Blum, Rhonda F. Souza, Massimiliano Di Pietro, Prasad G Iyer, Oliver Pech, Rebecca C. Fitzgerald, Peter D. Siersema

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Barrett oesophagus (BE), the only known histological precursor of oesophageal adenocarcinoma (EAC), is a condition in which the squamous epithelium of the oesophagus is replaced by columnar epithelium as an adaptive response to gastro-oesophageal reflux. EAC has one of the fastest rising incidences of cancers in Western countries and has a dismal prognosis. BE is usually detected during endoscopic examination, and diagnosis is confirmed by the histological presence of intestinal metaplasia. Advances in genomics and transcriptomics have improved our understanding of the pathogenesis and malignant progression of intestinal metaplasia. As the majority of EAC cases are diagnosed in individuals without a known history of BE, screening for BE could potentially decrease disease-related mortality. Owing to the pre-malignant nature of BE, endoscopic surveillance of patients with BE is imperative for early detection and treatment of dysplasia to prevent further progression to invasive EAC. Developments in endoscopic therapy have resulted in a major shift in the treatment of patients with BE who have dysplasia or early EAC, from surgical resection to endoscopic resection and ablation. In addition to symptom control by optimization of lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based on NSAIDs and statins are currently being investigated for BE management.

Original languageEnglish (US)
Article number35
JournalNature Reviews Disease Primers
Volume5
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Barrett Esophagus
Metaplasia
Epithelium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proton Pump Inhibitors
Non-Steroidal Anti-Inflammatory Agents
Therapeutics
Gastroesophageal Reflux
Genomics
Esophagus
Life Style
Adenocarcinoma
Pharmacology
Mortality
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Peters, Y., Al-Kaabi, A., Shaheen, N. J., Chak, A., Blum, A., Souza, R. F., ... Siersema, P. D. (2019). Barrett oesophagus. Nature Reviews Disease Primers, 5(1), [35]. https://doi.org/10.1038/s41572-019-0086-z

Barrett oesophagus. / Peters, Yonne; Al-Kaabi, Ali; Shaheen, Nicholas J.; Chak, Amitabh; Blum, Andrew; Souza, Rhonda F.; Di Pietro, Massimiliano; Iyer, Prasad G; Pech, Oliver; Fitzgerald, Rebecca C.; Siersema, Peter D.

In: Nature Reviews Disease Primers, Vol. 5, No. 1, 35, 01.12.2019.

Research output: Contribution to journalReview article

Peters, Y, Al-Kaabi, A, Shaheen, NJ, Chak, A, Blum, A, Souza, RF, Di Pietro, M, Iyer, PG, Pech, O, Fitzgerald, RC & Siersema, PD 2019, 'Barrett oesophagus', Nature Reviews Disease Primers, vol. 5, no. 1, 35. https://doi.org/10.1038/s41572-019-0086-z
Peters Y, Al-Kaabi A, Shaheen NJ, Chak A, Blum A, Souza RF et al. Barrett oesophagus. Nature Reviews Disease Primers. 2019 Dec 1;5(1). 35. https://doi.org/10.1038/s41572-019-0086-z
Peters, Yonne ; Al-Kaabi, Ali ; Shaheen, Nicholas J. ; Chak, Amitabh ; Blum, Andrew ; Souza, Rhonda F. ; Di Pietro, Massimiliano ; Iyer, Prasad G ; Pech, Oliver ; Fitzgerald, Rebecca C. ; Siersema, Peter D. / Barrett oesophagus. In: Nature Reviews Disease Primers. 2019 ; Vol. 5, No. 1.
@article{b407ae33ab04490eb361abe91d5cec96,
title = "Barrett oesophagus",
abstract = "Barrett oesophagus (BE), the only known histological precursor of oesophageal adenocarcinoma (EAC), is a condition in which the squamous epithelium of the oesophagus is replaced by columnar epithelium as an adaptive response to gastro-oesophageal reflux. EAC has one of the fastest rising incidences of cancers in Western countries and has a dismal prognosis. BE is usually detected during endoscopic examination, and diagnosis is confirmed by the histological presence of intestinal metaplasia. Advances in genomics and transcriptomics have improved our understanding of the pathogenesis and malignant progression of intestinal metaplasia. As the majority of EAC cases are diagnosed in individuals without a known history of BE, screening for BE could potentially decrease disease-related mortality. Owing to the pre-malignant nature of BE, endoscopic surveillance of patients with BE is imperative for early detection and treatment of dysplasia to prevent further progression to invasive EAC. Developments in endoscopic therapy have resulted in a major shift in the treatment of patients with BE who have dysplasia or early EAC, from surgical resection to endoscopic resection and ablation. In addition to symptom control by optimization of lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based on NSAIDs and statins are currently being investigated for BE management.",
author = "Yonne Peters and Ali Al-Kaabi and Shaheen, {Nicholas J.} and Amitabh Chak and Andrew Blum and Souza, {Rhonda F.} and {Di Pietro}, Massimiliano and Iyer, {Prasad G} and Oliver Pech and Fitzgerald, {Rebecca C.} and Siersema, {Peter D.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41572-019-0086-z",
language = "English (US)",
volume = "5",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Barrett oesophagus

AU - Peters, Yonne

AU - Al-Kaabi, Ali

AU - Shaheen, Nicholas J.

AU - Chak, Amitabh

AU - Blum, Andrew

AU - Souza, Rhonda F.

AU - Di Pietro, Massimiliano

AU - Iyer, Prasad G

AU - Pech, Oliver

AU - Fitzgerald, Rebecca C.

AU - Siersema, Peter D.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Barrett oesophagus (BE), the only known histological precursor of oesophageal adenocarcinoma (EAC), is a condition in which the squamous epithelium of the oesophagus is replaced by columnar epithelium as an adaptive response to gastro-oesophageal reflux. EAC has one of the fastest rising incidences of cancers in Western countries and has a dismal prognosis. BE is usually detected during endoscopic examination, and diagnosis is confirmed by the histological presence of intestinal metaplasia. Advances in genomics and transcriptomics have improved our understanding of the pathogenesis and malignant progression of intestinal metaplasia. As the majority of EAC cases are diagnosed in individuals without a known history of BE, screening for BE could potentially decrease disease-related mortality. Owing to the pre-malignant nature of BE, endoscopic surveillance of patients with BE is imperative for early detection and treatment of dysplasia to prevent further progression to invasive EAC. Developments in endoscopic therapy have resulted in a major shift in the treatment of patients with BE who have dysplasia or early EAC, from surgical resection to endoscopic resection and ablation. In addition to symptom control by optimization of lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based on NSAIDs and statins are currently being investigated for BE management.

AB - Barrett oesophagus (BE), the only known histological precursor of oesophageal adenocarcinoma (EAC), is a condition in which the squamous epithelium of the oesophagus is replaced by columnar epithelium as an adaptive response to gastro-oesophageal reflux. EAC has one of the fastest rising incidences of cancers in Western countries and has a dismal prognosis. BE is usually detected during endoscopic examination, and diagnosis is confirmed by the histological presence of intestinal metaplasia. Advances in genomics and transcriptomics have improved our understanding of the pathogenesis and malignant progression of intestinal metaplasia. As the majority of EAC cases are diagnosed in individuals without a known history of BE, screening for BE could potentially decrease disease-related mortality. Owing to the pre-malignant nature of BE, endoscopic surveillance of patients with BE is imperative for early detection and treatment of dysplasia to prevent further progression to invasive EAC. Developments in endoscopic therapy have resulted in a major shift in the treatment of patients with BE who have dysplasia or early EAC, from surgical resection to endoscopic resection and ablation. In addition to symptom control by optimization of lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based on NSAIDs and statins are currently being investigated for BE management.

UR - http://www.scopus.com/inward/record.url?scp=85066864044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066864044&partnerID=8YFLogxK

U2 - 10.1038/s41572-019-0086-z

DO - 10.1038/s41572-019-0086-z

M3 - Review article

VL - 5

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

IS - 1

M1 - 35

ER -